| Journal | Frontiers in neurology |
| Study Type | Clinical Study |
| Population | Human participants |
This consensus from Italian neurologists addresses a growing clinical challenge: managing persistent symptoms and silent progression in MS patients who appear stable on high-efficacy therapies. The focus on endocannabinoid system enhancement represents a shift toward treating residual disease rather than just preventing relapses.
Italian neurologists convened to develop a treatment algorithm for relapse-free multiple sclerosis patients experiencing ongoing symptoms despite high-efficacy therapies. The consensus proposes enhancing the endocannabinoid system through cannabinoid medications combined with lifestyle interventions including diet and exercise to address spasticity and associated residual symptoms. This represents expert clinical opinion rather than controlled trial data, focusing on the reality that many MS patients continue to experience progression and symptoms even when relapse-free on modern therapeutics.
โI appreciate this pragmatic approach to a real clinical gap – patients stable on disease-modifying therapies but still struggling with spasticity and quality of life. The algorithm provides structure for something many of us are already doing case-by-case.โ
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.